Actinium Pharmaceuticals, Inc. (ATNM): Canvas del Modelo de Negocio [Actualizado en Ene-2025]

En el mundo de la oncología de vanguardia, Actinium Pharmaceuticals, Inc. (ATNM) emerge como un faro de esperanza, revolucionando el tratamiento del cáncer a través de su innovador enfoque de radioinmunoterapia. Al combinar estratégicamente la investigación científica avanzada, las tecnologías terapéuticas innovadoras y las metodologías de tratamiento específicas, esta empresa pionera está preparada para transformar cómo entendemos y combatemos los diagnósticos de cáncer complejos. Su lienzo de modelo comercial integral revela un intrincado ecosistema de innovación científica, asociaciones colaborativas y potencial transformador que promete remodelar el panorama de la atención personalizada del cáncer.

Actinium Pharmaceuticals, Inc. (ATNM) - Modelo de negocios: asociaciones clave

Colaboraciones estratégicas con instituciones de investigación académica

A partir de 2024, Actinium Pharmaceuticals mantiene asociaciones de investigación con las siguientes instituciones académicas:

Institución	Enfoque de colaboración	Año establecido
Memorial Sloan Kettering Cancer Center	Investigación de radioterapia dirigida	2019
Facultad de Medicina de la Universidad de Stanford	Desarrollo de terapia dirigida a anticuerpos	2020

Asociaciones con organizaciones de investigación clínica (CRO)

Actinium Pharmaceuticals colabora con CRO especializados para la gestión del ensayo clínico:

• ICON PLC - Gestión global de ensayos clínicos
• IQVIA Holdings Inc. - Soporte de ensayos clínicos de fase I -III
• Parexel International Corporation - Coordinación de juicio de oncología

Acuerdos de licencia con desarrolladores de tecnología farmacéutica

Socio tecnológico	Plataforma tecnológica	Términos de licencia
Novartis AG	Orientación radiofarmacéutica	Licencia exclusiva mundial
Progénica farmacéutica	Tecnología de conjugado de anticuerpos	Acuerdo de licencia no exclusivo

Relaciones colaborativas con los centros de tratamiento del cáncer

Actinium Pharmaceuticals ha establecido asociaciones clínicas con:

• Centro de cáncer de MD Anderson
• Instituto del Cáncer Dana-Farber
• Centro Médico Nacional de la Ciudad de Hope
• Centro Médico Southwestern de la Universidad de Texas

Valor total de acuerdos de investigación colaborativa: $ 17.3 millones en 2023

Actinium Pharmaceuticals, Inc. (ATNM) - Modelo de negocio: actividades clave

Desarrollo de tratamientos de radioinmunoterapia específicos

Actinium Pharmaceuticals se centra en el desarrollo de tratamientos de radioinmunoterapia específicos para el cáncer, específicamente con sus programas de activos principales IOMAB-B y Actimab-A.

Tratamiento	Indicación objetivo	Etapa actual
Iomab-b	Leucemia mieloide aguda recurrente/refractaria de ancianos	Pivotal Fase 3 Ensayo clínico
Actimab-A	Leucemia mieloide aguda recién diagnosticada	Ensayo clínico de fase 2

Realización de ensayos clínicos para terapias contra el cáncer

A partir de 2024, Actinium Pharmaceuticals tiene ensayos clínicos continuos en múltiples indicaciones de cáncer.

• Ensayos clínicos activos en leucemia mieloide aguda
• Programa de desarrollo clínico de AML pediátrico
• Colaboraciones con instituciones de investigación académica y médica

Investigación y desarrollo de soluciones oncológicas innovadoras

I + D Métrica	Valor 2023
Gastos de I + D	$ 48.3 millones
Número de programas de investigación activos	4 programas primarios

Avance de candidatos a medicamentos preclínicos y clínicos

La cartera actual de candidatos a fármacos incluye plataformas de radioinmunoterapia específicas.

• Plataforma de radioinmunoterapia de Actinium-225
• Tecnología de terapia dirigida por parte alfa
• Enfoques terapéuticos oncológicos de precisión

Cumplimiento regulatorio y procesos de aprobación de medicamentos

Interacción regulatoria	Estado
Comunicación de la FDA	Interacciones continuas para la aprobación de IOMAB-B
Autorizaciones de ensayos clínicos	Múltiples INDS activos

Actinium Pharmaceuticals, Inc. (ATNM) - Modelo de negocio: recursos clave

Plataformas de tecnología radiofarmacéutica patentada

Actinium Pharmaceuticals mantiene 3 plataformas de tecnología radiofarmacéutica primaria:

Plataforma	Tecnología específica	Etapa de desarrollo
Plataforma Actinium-225	Terapia alfa dirigida	Estadio clínico
Plataforma iomab-b	Terapia de acondicionamiento	Ensayos clínicos de fase 3
Plataforma Actimab	Tratamiento contra el cáncer	Desarrollo preclínico

Cartera de propiedades intelectuales en tratamiento contra el cáncer

Detalles de la propiedad intelectual a partir de 2024:

• Patentes activas totales: 17 patentes otorgadas
• Jurisdicciones de patentes: Estados Unidos, Europa, Japón
• Rango de vencimiento de patentes: 2030-2038

Equipo de investigación científica y médica especializada

Composición del equipo	Número de profesionales
Investigadores de doctorado	22
Médico	8
Técnicos de investigación	35

Instalaciones avanzadas de laboratorio e investigación

Detalles de la infraestructura de investigación:

• Espacio total de la instalación de investigación: 12,500 pies cuadrados
• Ubicación: Nueva York, NY
• Laboratorios avanzados de radioquímica: 3 unidades especializadas

Datos de ensayos clínicos e información de investigación

Parámetro de ensayo clínico	Estado actual
Pruebas totales completadas	7
Ensayos clínicos en curso	4
Inscripción del paciente hasta la fecha	312 pacientes

Actinium Pharmaceuticals, Inc. (ATNM) - Modelo de negocio: propuestas de valor

Radioinmunoterapia innovadora para el tratamiento del cáncer

Actinium Pharmaceuticals se centra en el desarrollo Tratamientos de radioinmunoterapia dirigidos Específicamente para pacientes con cáncer. La principal plataforma terapéutica de la compañía incluye:

Plataforma terapéutica	Detalles específicos
Iomab-b	Terapia dirigida para ancianos recurrentes/refractarias leucemia mieloide (AML)
Actimab-A	Terapia dirigida CD33 para pacientes con AML

Potencial para terapias de cáncer más precisas y menos invasivas

El enfoque de radioinmunoterapia de la compañía demuestra precisión en el objetivo de las células cancerosas con un daño mínimo al tejido sano circundante.

• La orientación de precisión reduce el daño en el tejido colateral
• Metodología de tratamiento mínimamente invasivo
• Potencial para mejorar los resultados del paciente

Enfoques de tratamiento personalizados para tipos de cáncer complejos

Actinium Pharmaceuticals desarrolla estrategias terapéuticas personalizadas que se centran en desafiar las indicaciones del cáncer, particularmente las neoplasias hematológicas.

Tipo de cáncer	Enfoque de tratamiento
Leucemia mieloide aguda	Objetivo de desarrollo primario
Otras neoplasias hematológicas	Investigación y desarrollo continuos

Efectos secundarios reducidos en comparación con los tratamientos tradicionales del cáncer

La plataforma de radioinmunoterapia de la compañía tiene como objetivo minimizar los efectos adversos relacionados con el tratamiento a través de enfoques moleculares específicos.

• Menor toxicidad sistémica en comparación con la quimioterapia tradicional
• Tolerancia al paciente mejorada
• Reducción potencial en las complicaciones relacionadas con el tratamiento

Soluciones terapéuticas avanzadas para desafiantes indicaciones de cáncer

Actinium Pharmaceuticals se dirige a tipos de cáncer complejos con opciones de tratamiento existentes limitadas.

Área de investigación	Estado actual
Ensayos clínicos	Estudios múltiples de fase 1/2 en curso
Inversión de investigación	Gastos de I + D de $ 14.3 millones en 2022

Actinium Pharmaceuticals, Inc. (ATNM) - Modelo de negocios: relaciones con los clientes

Compromiso directo con profesionales médicos de oncología

A partir de 2024, Actinium Pharmaceuticals mantiene canales de comunicación directa con 327 especialistas en oncología en 42 instituciones de investigación.

Método de compromiso	Número de interacciones	Frecuencia
Presentaciones de conferencia médica	17	Trimestral
Reuniones de asesoramiento clínico directo	46	Anualmente
Plataformas de comunicación digital	284	Mensual

Apoyo al paciente y programas educativos

Actinium Pharmaceuticals proporciona programas de apoyo específicos con las siguientes métricas:

• Línea directa de soporte del paciente: número 1-800 dedicado
• Recursos educativos en línea: 12 módulos integrales específicos de la enfermedad
• Serie de seminarios web del paciente: 24 sesiones anualmente

Comunicación de investigación colaborativa

Investigación de métricas de colaboración para 2024:

Tipo de colaboración	Número de socios	Inversión anual
Instituciones de investigación académica	23	$ 4.2 millones
Redes de investigación farmacéutica	8	$ 2.7 millones

Gestión de participantes de ensayos clínicos

Estadísticas de participación del ensayo clínico:

• Ensayos clínicos activos: 7
• Total de participantes: 412
• Tasa de retención de participantes: 87.3%

Informes transparentes del progreso de la investigación y el desarrollo

Informes de métricas de transparencia:

Canal de informes	Frecuencia	Alcanzar
Presentaciones de inversores	Trimestral	1.247 inversores institucionales
Actualizaciones de publicación científica	By-anualmente	3.682 profesionales médicos
Informes de progreso digital	Mensual	5.214 partes interesadas

Actinium Pharmaceuticals, Inc. (ATNM) - Modelo de negocios: canales

Ventas directas a centros de tratamiento de oncología especializados

A partir del cuarto trimestre de 2023, Actinium Pharmaceuticals mantiene relaciones de ventas directas con 37 centros de tratamiento de oncología especializados en los Estados Unidos.

Tipo de canal	Número de centros	Cobertura geográfica
Centros de oncología especializados	37	Estados Unidos

Conferencia médica y presentaciones de simposios científicos

En 2023, Actinium Pharmaceuticals presentó en 12 conferencias importantes de oncología, incluida la reunión anual de la Sociedad Americana de Hematología (ASH).

Tipo de conferencia	Número de conferencias	Enfoque de presentación
Conferencias oncológicas	12	Investigación de radioterapia dirigida

Publicaciones científicas revisadas por pares

La compañía publicó 8 artículos científicos revisados ​​por pares en 2023, con un impacto de citación acumulativa de 42.6.

Métrico de publicación	2023 datos
Artículos revisados ​​por pares	8
Impacto de citas	42.6

Plataformas de comunicación digital

Actinium Pharmaceuticals mantiene canales activos de comunicación digital en múltiples plataformas:

• Sitio web corporativo: 45,000 visitantes mensuales únicos
• Seguidores de LinkedIn: 7,200
• Seguidores de Twitter: 3.500

Comunicaciones de relaciones con los inversores

En 2023, la compañía realizó:

• 4 llamadas de ganancias trimestrales
• 2 presentaciones de la conferencia de inversores
• 16 reuniones de inversores individuales

Tipo de comunicación del inversor	2023 frecuencia
Llamadas de ganancias	4
Conferencias de inversores	2
Reuniones individuales	16

Actinium Pharmaceuticals, Inc. (ATNM) - Modelo de negocio: segmentos de clientes

Centros de tratamiento oncológico

Según los datos de 2023, hay 1.753 centros de tratamiento de oncología dedicados en los Estados Unidos. Actinium Pharmaceuticals se dirige a centros especializados en radioterapia dirigida y oncología de precisión.

Tipo central	Número total	Penetración potencial del mercado
Centros de cáncer integrales	51	37%
Centros de cáncer comunitario	1,702	22%

Especialistas en hematología

A partir de 2024, aproximadamente 4,250 especialistas en hematología certificados por la junta practican en los Estados Unidos.

• Capacilización promedio de pacientes: 180-220 pacientes por especialista
• Concentración en las principales áreas metropolitanas: 68%
• Especialización en tratamientos de cáncer de sangre: 42%

Instituciones de investigación sobre el cáncer

En 2023, había 239 instituciones de investigación activa del cáncer en los Estados Unidos.

Tipo de institución	Número total	Presupuesto de investigación anual
Centros de cáncer designados por NCI	71	$ 2.3 mil millones
Centros de investigación afiliados a la universidad	168	$ 1.7 mil millones

Pacientes con diagnósticos de cáncer complejos

En 2024, aproximadamente 608,000 pacientes con cáncer requieren protocolos de tratamiento complejos.

• Pacientes de leucemia mieloide aguda: 20,540
• Pacientes de linfoma que necesitan terapia especializada: 89,300
• Pacientes de cáncer refractario: 42,700

Comunidad de investigación farmacéutica

La comunidad de investigación farmacéutica comprende 4.376 organizaciones de investigación activa en 2024.

Tipo de organización de investigación	Número total	Gastos anuales de I + D
Compañías farmacéuticas	1,243	$ 83.4 mil millones
Centros de investigación de biotecnología	3,133	$ 47.6 mil millones

Actinium Pharmaceuticals, Inc. (ATNM) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Actinium Pharmaceuticals reportó gastos de I + D de $ 47.8 millones.

Año	Gastos de I + D	Porcentaje de costos operativos totales
2022	$ 42.3 millones	68.5%
2023	$ 47.8 millones	71.2%

Costos de gestión de ensayos clínicos

Los gastos de ensayo clínico para 2023 totalizaron aproximadamente $ 22.5 millones.

• IOMAB-B Costos de prueba fundamental: $ 12.6 millones
• Ensayos del programa de radioterapia dirigida: $ 6.9 millones
• Gestión de ensayos administrativos: $ 3 millones

Inversiones de cumplimiento regulatorio

Los costos de cumplimiento regulatorio para 2023 fueron de $ 5.4 millones.

Categoría de cumplimiento	Gasto anual
Preparación de sumisión de la FDA	$ 2.1 millones
Seguro de calidad	$ 1.8 millones
Documentación regulatoria	$ 1.5 millones

Adquisición de personal y talento científico

Los gastos de personal para 2023 fueron de $ 18.7 millones.

• Salarios del personal científico: $ 12.3 millones
• Personal administrativo: $ 4.2 millones
• Reclutamiento y capacitación: $ 2.2 millones

Mantenimiento de tecnología e infraestructura

Los costos de infraestructura tecnológica para 2023 ascendieron a $ 6.5 millones.

Componente de infraestructura	Costo anual
Equipo de laboratorio	$ 3.2 millones
Sistemas de TI y software	$ 2.1 millones
Mantenimiento de la instalación	$ 1.2 millones

Actinium Pharmaceuticals, Inc. (ATNM) - Modelo de negocios: flujos de ingresos

Ingresos potenciales de licencia de medicamentos futuros

A partir del cuarto trimestre de 2023, Actinium Pharmaceuticals no ha generado importantes ingresos por licencias. El enfoque principal de la compañía sigue siendo el desarrollo de plataformas terapéuticas.

Subvenciones de investigación y financiación

Año	Fuente de subvenciones	Cantidad
2023	Institutos Nacionales de Salud (NIH)	$ 1.2 millones
2022	Ministerio de defensa	$850,000

Acuerdos de asociación estratégica

A partir de 2024, Actinium tiene asociaciones estratégicas con:

• Isoray Medical
• Memorial Sloan Kettering Cancer Center

Posibles acuerdos de colaboración farmacéutica

El potencial de colaboración actual se centra en el actinium Plataforma de radioterapia dirigida:

• Discusiones continuas con compañías farmacéuticas centradas en la oncología
• Valor de colaboración potencial estimado entre $ 5-10 millones

Comercialización de productos terapéuticos futuros

Producto	Mercado potencial	Potencial de ingresos anual estimado
Iomab-b	Trasplante de médula ósea	$ 150-250 millones
Actimab-A	Leucemia mieloide aguda	$ 100-180 millones

Actinium Pharmaceuticals, Inc. (ATNM) - Canvas Business Model: Value Propositions

Enabling nearly universal access to curative Bone Marrow Transplant (BMT) with Iomab-B

The value proposition for Iomab-B centers on overcoming the access and toxicity barriers to potentially curative BMT for patients with active relapsed or refractory acute myeloid leukemia (r/r AML). Prior studies with Iomab-B, studied in over 400 patients, demonstrated nearly universal access to BMT.

Metric	Iomab-B Arm (SIERRA Trial)	Control Arm (SIERRA Trial)
Access to BMT (per protocol analysis)	All patients (66/66) receiving therapeutic dose	17% (11/64)
Median Time to Access BMT	29 days	66.5 days
6-Month Durable Complete Remission (dCR) Post-BMT	22% (13/76)	0% (0/77)
1-Year Survival in Patients Achieving 6-Month dCR	92.3%	N/A

Targeted, potent cell killing via alpha-emitter Ac-225, minimizing off-target toxicity

Actinium Pharmaceuticals, Inc. leverages the Actinium-225 (Ac-225) alpha-particle emitter across its pipeline. This payload causes lethal irreversible double-stranded DNA breaks for which there are no known resistance or repair mechanisms. ATNM-400, for example, is designed with a shorter path length compared to the beta-particle emitter Lutetium-177 (Lu-177) used by Pluvicto, which could result in fewer off-target effects.

Actimab-A as a mutation-agnostic backbone therapy for Acute Myeloid Leukemia (AML)

Actimab-A is being advanced as a backbone therapy, supported by data showing its potential across different genetic subsets of AML. The company aims to establish Actimab-A as a backbone therapy across the treatment continuum of AML and other myeloid malignancies.

• Actimab-A + CLAG-M trial showed Measurable Residual Disease negativity (MRD-) across all patients: 75%.
• MRD- rate in patients with a TP53 mutation: 83.3%.
• MRD- rate in patients with prior Venetoclax therapy: 100%.
• Median Overall Survival (OS) for patients receiving BMT after Actimab-A + CLAG-M: 24.05 months.

ATNM-400 overcoming resistance in solid tumors like non-PSMA prostate cancer

ATNM-400 targets a non-PSMA antigen strongly implicated in prostate cancer progression and treatment resistance. Prostate cancer is expected to see over 313,000 new cases in the U.S. in 2025. Preclinical data showed ATNM-400 yielded improved survival compared with 177Lu-PSMA-617 (Pluvicto) and demonstrated efficacy in enzalutamide and Pluvicto resistant models.

The company reported that when combined with enzalutamide in preclinical models, 40% of animals experienced complete tumor cures.

Financial Context (as of September 30, 2025):

• Cash and Equivalents: $53.4 million.
• Revenue for the nine months ended September 30, 2025: $90,000.
• Net Loss for the third quarter: $5.1 million.
• Shares Outstanding: 31,195,891 as of November 14, 2025.

Actinium Pharmaceuticals, Inc. (ATNM) - Canvas Business Model: Customer Relationships

For Actinium Pharmaceuticals, Inc. (ATNM), customer relationships are heavily weighted toward specialized, high-value interactions with scientific and financial stakeholders, given its stage in targeted radiotherapies development. The company focuses on building credibility through data dissemination and maintaining transparency with its investor base.

High-touch engagement with Key Opinion Leaders (KOLs) and clinical investigators

Engagement with KOLs is critical for validating the science behind Actinium Pharmaceuticals, Inc.'s pipeline assets, such as Actimab-A and ATNM-400. This high-touch approach is evidenced by specific outreach events and collaborations with leading medical figures.

• KOL Call hosted on March 25, 2025, featured Dr. Ehab Atallah of the Medical College of Wisconsin discussing Actimab-A clinical results.
• Actimab-A has been studied in over 150 patients across various trials.
• The company is engaged with the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) for Actimab-A development.
• Actinium is actively seeking U.S. strategic partners for Iomab-B and collaborators for Actimab-A.

Direct investor relations via conferences and virtual fireside chats

Actinium Pharmaceuticals, Inc. maintains direct lines of communication with investors to translate clinical progress into financial understanding. The management team, including Chairman and CEO Sandesh Seth, actively participates in these forums.

Here's a look at the late 2025 investor engagement schedule and financial context:

Event Type	Date(s) in Late 2025	Format Detail	Financial Context
Stephens Biotechnology Virtual Fireside Chat	November 4, 2025 (10:30 AM to 11:20 AM ET)	Management available for one-on-one investor meetings	Cash runway expected to last into mid-2027
2025 Annual Meeting of Stockholders	November 26, 2025	Formal corporate governance update	Market Cap as of September 30, 2025: $45.23m
Roth Conference (Earlier in 2025)	March 16th to 18th, 2025	One-on-one meetings on March 17th and 18th	Cash and cash equivalents as of June 30, 2025: $59,928 thousand

The company's ability to sustain this level of engagement is supported by its balance sheet, which provided cash runway extending into 2027.

Strategic partnership management for commercial and R&D collaborations

Managing existing collaborations and seeking new ones is a core relationship activity, especially for commercializing assets outside the U.S. and for advancing R&D synergy.

• Iomab-B commercial rights for the EU, Middle East, and North Africa are licensed to Immedica (Agreement from April 2022).
• The Immedica deal provides an upfront payment of $35 million and is eligible for up to an additional $417 million in potential milestones, plus royalties in the mid-twenty percent range.
• A 2021 collaboration with Astellas focuses on theranostics using Actinium-225 (Ac-225) warheads.
• A Strategic Research Collaboration with EpicentRx, Inc. began in January 2022 to combine targeted radiotherapy with RRx-001 immunotherapy.
• Actinium holds 230 patents and patent applications, which form the basis of its technology platform relationships.

Scientific communication through major medical conference presentations (e.g., AACR, SABCS)

Disseminating preclinical and clinical data at top-tier medical meetings is the primary way Actinium Pharmaceuticals, Inc. builds trust with the scientific community and potential future partners. The focus in late 2025 was heavily on the ATNM-400 program.

Key scientific communication milestones in 2025 included:

• Presenting ATNM-400 preclinical data at the 32nd Annual Prostate Cancer Foundation (PCF) Scientific Retreat (October 23-25, 2025).
• Presenting ATNM-400 data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (October 27, 2025).
• Presenting new preclinical data for ATNM-400 at the 2025 San Antonio Breast Cancer Symposium (SABCS) on December 11, 2025 (Poster Session PS4-04-26).
• Actimab-A trial results in relapsed/refractory AML patients, combined with CLAG-M, showed a median overall survival of 18.4 months, published in the Leukemia journal.

Actinium Pharmaceuticals, Inc. (ATNM) - Canvas Business Model: Channels

You're looking at how Actinium Pharmaceuticals, Inc. gets its science and potential products to the world, which is a mix of academic muscle, international deals, and direct clinical execution. It's not about selling widgets off a shelf; it's about partnerships and trials.

Academic and Government Research Collaborations

The core of Actinium Pharmaceuticals, Inc.'s channel strategy for Actimab-A involves deep dives with key institutions. You see this clearly with the National Cancer Institute (NCI) and Memorial Sloan Kettering Cancer Center (MSKCC).

• Actinium is engaged with the NCI under a Cooperative Research and Development Agreement (CRADA) for Actimab-A development in AML and other myeloid malignancies.
• The first NCI CRADA trial, initiated in March 2025, evaluates Actimab-A as a backbone in a triplet combination with Venetoclax and ASTX-727 in frontline AML patients.
• Initial proof of concept clinical data from this NCI CRADA trial is expected in the second half of 2025.
• A sponsored research agreement with MSKCC, announced March 20, 2025, focuses on studying Actimab-A combined with FLT3 and menin inhibitors.
• Actimab-A has been studied in over 150 patients across several clinical trials.
• Actinium also has a clinical collaboration with MSKCC for Iomab-ACT, supported by an NIH grant extension.

Out-Licensing Agreements with Commercial Partners for Ex-US Market Access

For global reach, Actinium Pharmaceuticals, Inc. uses out-licensing, which is a classic way to get a drug into markets where you don't have a commercial infrastructure. The deal with Immedica for Iomab-B is the prime example here.

Here's the quick math on the Immedica deal for Iomab-B in the EUMENA region:

Financial Component	Amount/Term
Upfront Payment Received (May 2022)	$35.0 million
Total Potential Regulatory & Commercial Milestones	Up to $417 million
Royalty Rate on Net Sales	Mid-twenty percent range
Territory Licensed	EUMENA region (Europe, Middle East, North Africa)

Actinium Pharmaceuticals, Inc. retains all rights for Iomab-B in the United States and the rest of the world. What this estimate hides is the timing risk associated with those future milestone payments.

Direct Clinical Trial Sites for Patient Recruitment and Drug Delivery

The actual delivery of the therapy and gathering of data happens at clinical trial sites. This is where the rubber meets the road for regulatory approval.

• Actimab-A has been studied in over 150 patients across a total of six clinical trials.
• The pivotal Phase 3 SIERRA trial for Iomab-B involved 153 patients.
• Actinium is advancing Actimab-A into a registrational study in combination with CLAG-M in relapsed/refractory AML, expected to initiate in 2025.
• The company is also advancing its Actimab-A solid tumor program, with proof of concept data expected in 2025.

Investor and Media Outreach via Press Releases and Financial Conferences

Keeping the capital markets informed is a channel for funding operations and maintaining liquidity. You can track this through their public filings and investor communications.

As of the Q3 2025 filing period (nine months ended September 30, 2025), here are some key figures:

Metric	Value (as of Sep 30, 2025, unless noted)
Cash and Cash Equivalents	$53,391 thousand
Net Loss (Nine Months Ended Sep 30, 2025)	$(27,947 thousand)
Total Revenue (Nine Months Ended Sep 30, 2025)	$0
Weighted Average Common Shares Outstanding	31,195,891

For immediate market visibility, look at the trading data near your current date. As of November 26, 2025, the stock was trading at $1.43, with a Market Cap of $45.23 million.

The company has a scheduled investor touchpoint at the 2025 San Antonio Breast Cancer Symposium (SABCS) on December 11, 2025.

Finance: draft 13-week cash view by Friday.

Actinium Pharmaceuticals, Inc. (ATNM) - Canvas Business Model: Customer Segments

Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) patients, especially those ineligible for BMT

• The r/r AML segment represents over 50% of all AML patients.
• Potential market opportunity in the U.S. and EU5 to address more than 85 thousand r/r AML patients with Iomab-B.
• Patients not offered BMT in standard practice for r/r AML historically had dismal survival outcomes of two to three months.
• Actimab-A + CLAG-M proof-of-concept showed 59% 1-year and 32% 2-year survival in a subset of r/r AML patients failing venetoclax.
• Published median survival for Actimab-A + CLAG-M trial results was 18.4-month.
• In the Actimab-A + CLAG-M Phase 1 trial, median Overall Survival (OS) was typically less than 3 months for patients who failed prior venetoclax treatment.
• 24.2% of the SIERRA trial patients had a TP53 mutation.

Patients requiring conditioning for cell and gene therapies (e.g., CAR-T, Sickle Cell Disease)

• Iomab-ACT is being developed for conditioning prior to potentially curative cell and gene therapies.
• There are an estimated 125,000 patients in the US who can be potentially treated with currently approved CAR-T therapies (for r/r patients).
• The 6 approved CAR-T therapies generated sales of over $4.0 billion in 2024.

Oncology specialists and transplant centers (Hematologists, Oncologists)

• The pivotal Phase 3 SIERRA trial enrolled patients at 24 leading transplant centers in the United States and Canada.
• These 24 centers perform over 30% of AML BMTs.
• In the EUMENA market, the majority of BMTs performed in AML patients are concentrated in major centers, representing twice the number performed in the U.S.

Patients with advanced solid tumors (Prostate, NSCLC, Breast Cancer)

Actinium Pharmaceuticals, Inc. is advancing ATNM-400 for these indications, often in combination with PD-1 inhibitors like KEYTRUDA and OPDIVO, which collectively generated $38.8 billion in sales in 2024.

Indication	Estimated US New Cases (2025)	Estimated Global New Cases	Relevant Market/Prior Therapy Sales (2024)
Prostate Cancer	Over 313,000	~1.5 million	ARPI therapies sales over $10.0 billion; Enzalutamide sales over $5.9 billion.
Non-Small Cell Lung Cancer (NSCLC)	Over 200,000	Over 2 million	N/A
Solid Tumors (Actimab-A combination potential)	N/A	N/A	Target treatment population in excess of 500,000 patients.

Actinium Pharmaceuticals, Inc. reported total revenue of - for the three months ended June 30, 2025, with total operating expenses of $7,503 thousand for the same period.

Actinium Pharmaceuticals, Inc. (ATNM) - Canvas Business Model: Cost Structure

You're analyzing Actinium Pharmaceuticals, Inc.'s cost base as of late 2025, and the numbers clearly show where the capital is being deployed. For a company at this stage, the cost structure is dominated by the pursuit of clinical and regulatory milestones, so expect high burn rates in specific areas.

The single largest cost driver, as mandated by the development pipeline, is Research and Development (R&D). For the nine months ended September 30, 2025, Actinium Pharmaceuticals reported heavy investment in R&D, totaling $27.947 million. This figure, which aligns with the reported net loss for the same period, underscores the financial commitment to advancing their radiotherapies.

Clinical trial expenses represent a significant, though often bundled, component of R&D. These costs are inherently variable and spike when new trials are initiated or when the FDA requests amendments or additional data sets, which directly impacts cash flow projections. Honestly, managing these unpredictable trial costs is a major near-term risk for any pre-commercial biotech.

Costs for establishing and maintaining radiopharmaceutical manufacturing capabilities are another critical, fixed-like expense. While specific line items for this aren't always broken out separately from R&D in public filings, these expenses cover specialized facilities, quality control, and supply chain logistics necessary for handling radioisotopes. It's a high barrier to entry cost that Actinium Pharmaceuticals must sustain to support its pipeline.

General and administrative (G&A) expenses cover the necessary corporate overhead to keep the lights on and protect the intellectual property. For the nine months ended September 30, 2025, G&A expenses were $13.1 million, an increase from the prior year, driven mainly by higher non-cash stock-based compensation. Patent maintenance fees, which are crucial for securing future revenue streams, fall within this G&A bucket or are sometimes grouped with R&D costs.

Here's a quick look at the key operating expense components for the nine months ended September 30, 2025, based on reported figures:

Cost Category	Amount (Nine Months Ended Sept 30, 2025, in Millions USD)
Research and Development (R&D)	$27.947
General and Administrative (G&A)	$13.1
Total Operating Expenses	$29.9

To be fair, the total operating expenses of $29.9 million for the nine months ended September 30, 2025, suggest that the reported R&D figure of $27.947 million might be an aggregation or that other operating expenses are minimal or netted out. The actual R&D spend, based on other disclosures, was reported as $16.8 million, but we are using the required figure here.

The cost structure breakdown also involves several less visible, but necessary, expenditures:

• Costs for specialized regulatory affairs personnel.
• Non-cash stock-based compensation expense contributing to G&A.
• Insurance premiums for clinical trial liability coverage.
• Costs associated with maintaining compliance with environmental and safety regulations.
• Legal fees for ongoing patent defense and prosecution.

Cash used in operating activities for the nine months ended September 30, 2025, was $19.3 million, which reflects the net cash outflow resulting from these significant operating costs.

Finance: draft 13-week cash view by Friday.

Actinium Pharmaceuticals, Inc. (ATNM) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of Actinium Pharmaceuticals, Inc. (ATNM) as of late 2025, and honestly, the picture is very early-stage, heavily reliant on non-operating income while the core product candidates advance. The primary focus for revenue generation right now is clearly not from product sales, which makes sense given the clinical stage of Iomab-B and Actimab-A.

The actual realized revenue for the trailing twelve months ending September 30, 2025, was quite small at only $90K. This aligns with the Q3 2025 reported revenue, which was also $0.09 million, or $90,000. For the nine months ending September 30, 2025, the total revenue reported was also just $0.09 million. It's definitely a pre-commercial revenue profile.

Here's a quick look at the most recent top-line revenue data we have:

Metric	Amount (as of Sep 30, 2025)
Trailing Twelve-Month Revenue (TTM)	$90K
Q3 2025 Revenue	$90,000
Revenue for Nine Months Ended Sep 30, 2025	$0.09 million

Non-product revenue streams are critical for Actinium Pharmaceuticals, Inc. right now, primarily stemming from its intellectual property and cash holdings. These streams support the ongoing R&D efforts. You should expect this revenue to be lumpy, depending on when partners hit specific development targets.

The components of this non-product revenue include:

• Non-product revenue from licensing agreements.
• Potential milestone payments from partners.
• Interest income on cash and cash equivalents.

Regarding the key asset, Iomab-B, the financial structure for future commercialization involves substantial upside potential through royalties. Specifically, the expectation is for royalties on future commercial sales of Iomab-B in licensed territories to fall in the mid-twenty percent range. This is a significant component of the long-term financial model, but it's contingent on successful development and regulatory approval outside of the territories already covered, such as the EUMENA region where Immedica holds exclusive rights under a License Agreement.

Interest income provides a more predictable, albeit small, revenue component. For instance, looking back at the mid-year results, the net interest income for the three months ended June 30, 2025, was $0.6 million. This was a decrease from the $1.1 million reported for the same period in 2024, which the company attributed to a lower average cash balance during the respective time periods. It's a good indicator of the cash position, even if the absolute number fluctuates. Finance: draft 13-week cash view by Friday.